Steven S Witkin1, Stefan Gerber, William J Ledger. 1. Division of Immunology and Infectious Diseases, Department of Obstetrics and Gynecology, Weill Medical College of Cornell University, New York, NY 10021, USA. switkin@mail.med.cornell.edu
Abstract
OBJECTIVE: We differentiated women with vulvar vestibulitis syndrome into subgroups on the basis of the time of symptom onset, a history of recurrent vulvovaginal candidiasis, and the interleukin-1 receptor antagonist gene polymorphism. STUDY DESIGN: One hundred sixty-two consecutive patients with strictly defined vulvar vestibulitis syndrome were asked to fill out a questionnaire with the assistance of their gynecologist. A buccal sample was collected from each subject for the analysis of interleukin-1 receptor antagonist gene polymorphism; vaginal and vestibular microbial investigations were performed. RESULTS: Symptoms began with the first act of coitus in 20.4% of patients. A history of a recurrent Candida vulvovaginal infection was reported in 42.6% of patients; 25.9% of the patients were positive for the homozygous interleukin-1 receptor antagonist 2,2 genotype. Women with primary vulvar vestibulitis syndrome differed from women with secondary vulvar vestibulitis syndrome; women with primary vulvar vestibulitis syndrome were younger at the time of the onset of the symptoms (23.8 vs 31.2 years, P <.0001) and had never been pregnant (84.8% vs 61.2%, P <.0001). Women with a history of recurrent Candida vulvovaginitis differed from the other subjects by having a higher frequency of constant vestibular pain (40.6% vs 20.4%, P =.005), a vaginal discharge (79.7% vs 45.2%, P <.0001), and dysuria (62.3% vs 29.0%, P =.0001). Women who were homozygous for interleukin-1 receptor antagonist 2,2 genotype had an earlier onset of symptoms (26 years) than did women who were allele 1 homozygotes (31.3 years, P <.05). They also had a shorter duration of symptoms (4.1 vs 5.9 years, P <.05) and a higher frequency of allergy (47.6% vs 23.4%, P =.002). Human papillomavirus in the vaginal vestibule occurred at a greater frequency in women who were homozygous for interleukin-1 receptor antagonist 2,2 genotype. CONCLUSION: Subgroups of women with vulvar vestibulitis syndrome may be differentiated by symptomatic and genetic variables.
OBJECTIVE: We differentiated women with vulvar vestibulitis syndrome into subgroups on the basis of the time of symptom onset, a history of recurrent vulvovaginal candidiasis, and the interleukin-1 receptor antagonist gene polymorphism. STUDY DESIGN: One hundred sixty-two consecutive patients with strictly defined vulvar vestibulitis syndrome were asked to fill out a questionnaire with the assistance of their gynecologist. A buccal sample was collected from each subject for the analysis of interleukin-1 receptor antagonist gene polymorphism; vaginal and vestibular microbial investigations were performed. RESULTS: Symptoms began with the first act of coitus in 20.4% of patients. A history of a recurrent Candida vulvovaginal infection was reported in 42.6% of patients; 25.9% of the patients were positive for the homozygous interleukin-1 receptor antagonist 2,2 genotype. Women with primary vulvar vestibulitis syndrome differed from women with secondary vulvar vestibulitis syndrome; women with primary vulvar vestibulitis syndrome were younger at the time of the onset of the symptoms (23.8 vs 31.2 years, P <.0001) and had never been pregnant (84.8% vs 61.2%, P <.0001). Women with a history of recurrent Candida vulvovaginitis differed from the other subjects by having a higher frequency of constant vestibular pain (40.6% vs 20.4%, P =.005), a vaginal discharge (79.7% vs 45.2%, P <.0001), and dysuria (62.3% vs 29.0%, P =.0001). Women who were homozygous for interleukin-1 receptor antagonist 2,2 genotype had an earlier onset of symptoms (26 years) than did women who were allele 1 homozygotes (31.3 years, P <.05). They also had a shorter duration of symptoms (4.1 vs 5.9 years, P <.05) and a higher frequency of allergy (47.6% vs 23.4%, P =.002). Human papillomavirus in the vaginal vestibule occurred at a greater frequency in women who were homozygous for interleukin-1 receptor antagonist 2,2 genotype. CONCLUSION: Subgroups of women with vulvar vestibulitis syndrome may be differentiated by symptomatic and genetic variables.
Authors: Melissa A Farmer; Anna M Taylor; Andrea L Bailey; Alexander H Tuttle; Leigh C MacIntyre; Zarah E Milagrosa; Halley P Crissman; Gary J Bennett; Alfredo Ribeiro-da-Silva; Yitzchak M Binik; Jeffrey S Mogil Journal: Sci Transl Med Date: 2011-09-21 Impact factor: 17.956
Authors: Ruby H N Nguyen; Charu Mathur; Erin M Wynings; David A Williams; Bernard L Harlow Journal: J Low Genit Tract Dis Date: 2015-01 Impact factor: 1.925
Authors: Aswathi Jayaram; Steven S Witkin; Xia Zhou; Celeste J Brown; Gustavo E Rey; Iara M Linhares; William J Ledger; Larry J Forney Journal: Pathog Dis Date: 2014-07-10 Impact factor: 3.166
Authors: Charles N Rudick; Mingchen Jiang; Ryan E Yaggie; Vladimir I Pavlov; Joseph Done; Charles J Heckman; Christopher Whitfield; Anthony J Schaeffer; David J Klumpp Journal: PLoS One Date: 2012-08-10 Impact factor: 3.240
Authors: David C Foster; Megan L Falsetta; Collynn F Woeller; Stephen J Pollock; Kunchang Song; Adrienne Bonham; Constantine G Haidaris; Chris J Stodgell; Susan P Messing; Michael Iadarola; Richard P Phipps Journal: Pain Date: 2015-03 Impact factor: 7.926